Medical Policy

Utilization Management and Clinical Medical Policy

Policy Name:	Policy Number:	Scope:	Origination Date:	Effective Date:
Lanreotide (Somatuline Depot®)	**MP-RX-FP-83-23**	☒ **MMM MA** ☒ **MMM MultiHealth**	**11/30/2023** **Last Review Date:** **7/1/2026**	**7/1/2026** **Frequently Revision:** **Annual**

Service Category:

☐ Anesthesia
☐ Surgery
☐ Radiology Procedures
☐ Pathology and Laboratory Procedures
☐ Medicine Services and Procedures
☐ Evaluation and Management Services
☐ DME/Prosthetics or Supplies
☒ Other: Part B Drugs

Service Description:

This document addresses the use of Lanreotide (Somatuline Depot) **,** a somatostatin analog approved by the Food and Drug Administration (FDA) for the treatment of acromegalia and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression free survival and carcinoid syndrome to reduce the frequency of short-acting somastatin analog rescue therapy.

Background Information:

Somatuline Depot may reduce gallbladder motility and lead to gallstone formation. Some may also experience hypoglycemia or hyperglycemia as a result of inhibition of the secretion of insulin and glucagon. The most common overall cardiac adverse reactions observed included sinus bradycardia, bradycardia, and hypertension. Somatuline Depot is provided as a single dose, prefilled syringe and administered as a deep subcutaneous injection.

Approved Indications

A. The long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.
B. The treatment of adult patients with unresectable, well- or moderately- differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.
C. The treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy.

Other Uses

A. Neuroendocrine Tumors, including GI Tract, Lung, Thymus, Pancreas, and Pheochromocytoma/Paraganglioma

Policy Name:	Policy Number:	Scope:	Origination Date:	Effective Date:
Lanreotide (Somatuline Depot®)	MP-RX-FP-83-23	☒ MMM MA ☒ MMM MultiHealth	11/30/2023	7/1/2026
			Last Review Date: 7/1/2026	Frequently Revision: Annual

Medical Necessity Guidelines:

When a drug is being reviewed for coverage under a member's medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

Lanreotide (Somatuline Depot®)

A. Criteria For Initial Approval (*Provider must submit documentation [such as office chart notes, lab results, pathology reports, imaging studies, and any other pertinent clinical information] supporting the patient's diagnosis for the drug and confirming that the patient has met **all** approval criteria.)*

Initial requests for Somatuline Depot (lanreotide) may be approved if the following criteria are met:

i. Individual has a diagnosis of acromegaly; **AND**

   A. Diagnosis of acromegaly has been confirmed by, or in consultation with, a board-certified endocrinologist who has reviewed and verified the test results (such as but not limited to: Insulin-like Growth Factor 1 levels; Oral Glucose Tolerance Test with associated Growth Hormone (GH) levels) that are indicative of a positive test; **AND**

   B. Meets one of the following criteria:

      1. Pre-treatment insulin-like growth factor-1 (IGF-1) level above the upper limit of normal based on age and gender for the reporting laboratory; **OR**
      2. Serum growth hormone (GH) level ≥ 1 µg/L after a 2-hour oral glucose tolerance test; **AND**

   C. Either of the following:

      1. Individual has had an inadequate response to surgery and/or radiotherapy; **OR**
      2. Surgery and/or radiotherapy are not an option (such as but not limited to, individual is an inappropriate candidate for surgical- or radiation-based therapy);

OR

ii. Individual has a diagnosis of unresectable, well-or moderately-differentiated, locally advanced or metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (Label, NCCN 2A)

OR

iii. Individual has a diagnosis of carcinoid syndrome.

OR

iv. Individual has a diagnosis of Neuroendocrine Tumors, including GI Tract, Lung, Thymus, Pancreas, and Pheochromocytoma/Paraganglioma (NCCN 2A) and used in one of the following ways:

Policy Name:	Policy Number:	Scope:	Origination Date:	Effective Date:
Lanreotide (Somatuline Depot®)	MP-RX-FP-83-23	☒ MMM MA ☒ MMM MultiHealth	11/30/2023	7/1/2026
			Last Review Date: 7/1/2026	Frequently Revision: Annual

A. To treat unresectable primary gastrinoma; **OR**
B. For symptomatic treatment of insulinoma tumors expressing somatostatin receptors; **OR**
C. For symptomatic treatment of glucagonoma; **OR**
D. Symptomatic treatment of tumors secreting vasoactive intestinal polypeptide (VIPoma); **OR**
E. For treatment of symptoms related to hormone hypersecretion and/or carcinoid syndrome; **OR**
F. For tumor control in patients with unresectable, locally advanced, and/or metastatic disease; **OR**
G. Individual is diagnosed with diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH)

B. Criteria For Continuation of Therapy

i. MMM considers continuation of Somatuline Depot therapy medically necessary in members requesting reauthorization for an indication listed in Section A above (Criteria for Initial Approval) when all approval criteria are met.
   A. Acromegaly: Documentation is provided that individual's IGF-1 levels remain less or equal to 1.0 X the upper limit of normal (ULN).
   B. Carcinoid syndrome, Neuroendocrine tumors, pheochromocytoma/ paraganglioma: Documentation is provided confirming that the individual is experiencing clinical benefit from therapy as evidenced by improvement or stabilization in clinical signs and symptoms since starting therapy.

C. Authorization Duration

i. Initial Approval Duration: 1 year
ii. Reauthorization Approval Duration: Up 1 year

D. Conditions Not Covered

Any other use is considered experimental, investigational, or unproven, including the following (this list may not be all inclusive):

i. Somatuline Depot (lanreotide) may not be approved when the above criteria are not met and for all other indications.

Policy Name:	Policy Number:	Scope:	Origination Date:	Effective Date:
Lanreotide (Somatuline Depot®)	**MP-RX-FP-83-23**	☒ MMM MA ☒ MMM MultiHealth	**11/30/2023** **Last Review Date:** **7/1/2026**	**7/1/2026** **Frequently Revision:** **Annual**

Limits or Restrictions:

A. Therapeutic Alternatives

The list below includes preferred alternative therapies recommended in the approval criteria and may be subject to prior authorization.

i. N/A

B. Quantity Limitations

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines. The chart below includes dosing recommendations as per the FDA-approved prescribing information.

Drug	Recommended Dosing Schedule
Lanreotide (Somatuline Depot) 60 mg/0.2 mL, 90 mg/0.3 mL, and 120 mg/0.5 mL single dose prefilled syringes	• Acromegaly: 90 mg every 4 weeks for 3 months. Dose is then adjusted based on GH and/or IGF-1 levels. • GEP-NETs: 120 mg every 4 weeks (maximum of one-120 mg/0.5 mL every 28 days) • Carcinoid Syndrome: 120 mg every 4 weeks (maximum of one-120 mg/0.5 mL every 28 days)
Exceptions	
• See full prescribing information for dosage adjustment in patients with acromegaly and renal or hepatic impairment.	

Policy Name:	Policy Number:	Scope:	Origination Date:	Effective Date:
Lanreotide (Somatuline Depot®)	MP-RX-FP-83-23	☒ MMM MA ☒ MMM MultiHealth	11/30/2023	7/1/2026
			Last Review Date: 7/1/2026	Frequently Revision: Annual

Codes Information:

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

ICD-10 Diagnostic Codes:

Codes	Description
C25.4	Malignant neoplasm of endocrine pancreas
C74.10-C74.12	Malignant neoplasm of medulla of adrenal gland
C74.90-C74.92	Malignant neoplasm of unspecified part of adrenal gland
C75.5	Malignant neoplasm of aortic body and other paraganglia
C7A.00-C7A.8	Malignant neuroendocrine tumors (carcinoid tumors)
C7B.00-C7B.8	Secondary neuroendocrine tumors
D3A.010-D3A.8	Benign neuroendocrine tumors
D37.9	Neoplasm of uncertain behavior of digestive organ, unspecified
E16.1	Other hypoglycemia
E16.3	Increased secretion of glucagon
E16.8	Other specified disorders of pancreatic internal secretion
E22.0	Acromegaly and pituitary gigantism
E34.0-E34.09	Carcinoid syndrome
J84.841	Neuroendocrine cell hyperplasia of infancy

HCPCS Codes:

Codes	Description
J1930	Injection, lanreotide, 1 mg [Somatuline Depot]
J1932	Injection, lanreotide, (cipla), 1 mg

Policy Name:	Policy Number:	Scope:	Origination Date:	Effective Date:
Lanreotide (Somatuline Depot®)	**MP-RX-FP-83-23**	☒ **MMM MA** ☒ **MMM MultiHealth**	**11/30/2023** **Last Review Date:** **7/1/2026**	**7/1/2026** **Frequently Revision:** **Annual**

Reference Information:

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. http://dailymed.nlm.nih.gov/dailymed/about.cfm. Updated periodically.
2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
3. Ipsen Biopharmaceuticals, Inc. (2024). *Somatuline® Depot (lanreotide) injection, for subcutaneous use: Prescribing information.* Revised July 2024. Accessed on April 30, 2026. https://d2rkmuse97gwnh.cloudfront.net/a88aa6d6-3ca0-4362-a711-d53c45ae33ff/7efe6ca1-e0de-461c-8986-e3c0dc105200/7efe6ca1-e0de-461c-8986-e3c0dc105200_source__v.pdf
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2026; Updated periodically.
5. NCCN Clinical Practice Guidelines in Oncology™. © 2025 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: nccn.org. Updated periodically.
    a. Neuroendocrine and Adrenal Tumors V2.2025. Revised May 28, 2025.

Federal and state laws or requirements, contract language, and Plan utilization management programs or polices may take precedence over the application of this clinical criteria.

Medical Policy

Utilization Management and Clinical Medical Policy

Policy Name:	Policy Number:	Scope:	Origination Date:	Effective Date:
Lanreotide (Somatuline Depot®)	**MP-RX-FP-83-23**	☒ **MMM MA** ☒ **MMM MultiHealth**	**11/30/2023** **Last Review Date:** **7/1/2026**	**7/1/2026** **Frequently Revision:** **Annual**

Policy History:

Type of Review	Summary of Changes	P&T Approval Date	UM/CMPC Approval Date
Annual Review	Added FDA approved indications and Other Uses to the Background Information. Updated diagnosis criteria for acromegaly and added continuation of use criteria. Coding Reviewed: Removed ICD-10 code D13.7; added ICD10 codes: added E34.00-E34.09, C25.4, E16.1, E16.3, C74.10-C74.12, C74.90-C74.92, C75.5. Updated quantity limits tables and references. Incorporated new policy template.	6/19/2026	7/1/2026
Annual review	Minimal changes; Word formatting, coding review: No changes.	8/25/2025	9/8/2025
Annual Review	Added Criteria for Continuation of Therapy, authorization duration, and conditions not covered; Added dose and quantity limits; Added the following statement to the criteria for initial approval section; Provider must submit documentation [such as office chart notes, lab results, pathology reports, imaging studies, and any other pertinent clinical information] supporting the patient's diagnosis for the drug and confirming that the patient has met all approval criteria; wording and formatting changes; coding reviewed: No changes	3/14/2025	4/2/2025
Policy Inception	Elevance Health's Medical Policy adoption.	N/A	11/30/2023